Cygnus, Inc.

Cygnus Therapeutic Systems

Ortho-mcneil Pharmaceutical Corp.

Animas Corporation

Animas Technologies, LLC

Cygnus Research Corporation

Cygnus Terapeutic Systems

Chia-Ming Chiang

Janan Jona

Bret Berner

Michael J Tierney

Janet A Tamada

Russell O Potts

Michael D Garrison

Gary W Cleary

Renee Ann Tenzel

Tung-Fen Chen

Jun Xia

Tsung-Min Hsu

Ooi Wong

Kenneth J Colley

Eric J Roos

Priti Joshi

Asha Ramdas

Tung F Chen

Kathleen C Farinas

Methods and devices are provided for measuring the concentration of target chemical analytes present in a biological system. Device configuration and/or measurement techniques are employed in order to reduce the effect of interfering species on sensor sensitivity. One important application of the invention involves a method and device for monitoring blood glucose values.

Monitoring of physiological analytes

Monitoring a physiological analytes

Device for monitoring of physiological analytes

A matrix for containing drugs for transdermal delivery systems is disclosed. The matrix, formed of a skin-adhesive acrylate copolymer, attains high rates of drug delivery without the addition of drug delivery rate enhancers. In preferred embodiments the matrix is used to administer steroids, in particular estradiol. Water-soluble polymers may be added as well.

Solid matrix system for transdermal drug delivery

A matrix for containing drugs for transdermal delivery systems is disclosed. The matrix formed of a skin-adhesive acrylate copolymer, attains high rates of drug delivery without the addition of drug delivery rate enhancers. In preferred embodiments the matrix is used to administer steroids, in particular estradiol. Water-soluble polymers may be added as well

High capacity drug reservoirs are provided for incorporation into transdermal drug delivery systems. The drug reservoirs are hydrogels formulated from polyurethanes crosslinked with diisocyanate crosslinking agents or cured with radiation in the presence of a photoinitator. Drug loading as high as 65 to 70 wt. % or higher can be achieved by absorbing drug formulation into the reservoir after hydrogel synthesis. Methods for making and using transdermal systems containing such reservoirs are provided as well.

Polyurethane hydrogel drug reservoirs for use in transdermal drug

Transdermal administration of certain indolone derivatives which are dopamine D.sub.2 agonists is described. The method involves treating an individual afflicted with Parkinson's disease by administering an indolone derivative, e.g., ropinirole base or a pharmaceutically acceptable ropinirole salt, through the skin or mucosal tissue, for a time period and at an administration rate effective to alleviate the symptoms of the disease. Pharmaceutical formulations and drug delivery systems for administering the drugs are provided as well.

Transdermal administration of ropinirole and analogs thereof

A combination permeation enhancer for increasing the permeability of skin to sex steroids such as estrogens and progestogens comprising a polyhydric thioalcohol of 2 to 6 carbon atoms having at least one mercapto group and at least one hydroxy group and an aliphatic carboxylic acid of 8 to 24 carbon atoms or an ester thereof.

Skin permeation enhancer composition for use with sex steroids

A skin or buccal patch for providing nicotine replacement therapy which comprises a matrix type laminated composite in which the matrix is composed of a mixture of nicotine in a polymer wherein the amount of nicotine in the matrix, diffusion coefficient of nicotine in the matrix and the thickness of matrix are such that the release of nicotine is: (1) controlled by the patch; (2) rapid and at a relatively high flux over the prescribed wearing time of patch; and (3) such that a substantial proportion of the nicotine initially in the patch has been released at the end of the prescribed wearing time.

Method and device for providing nicotine replacement therapy

Matrix-type transdermal drug delivery devices for administering potent steroids such as ethinyl estradiol at a low flux steady-state rate over a multi-day period comprising a laminate of: (a) an occlusive backing layer and (b) a matrix layer of the drug completely dissolved at a loading of below 0.5% by weight in a 2-ethylhexyl acrylate copolymer.

Low flux matrix system for delivering potent drugs transdermally

Growing community of inventors

Foster City, CA, United States of America

Chia-Ming Chiang